Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on November 9, 2016. The report discloses executive compensation adjustments approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation changes.
Material Changes
On November 9, 2016, the Company awarded Andrew Rasdal, President and Chief Executive Officer, the following compensation adjustments:
- A one-time discretionary cash bonus of $250,000.
- An increase in annual base salary from $400,000 to $650,000, effective November 1, 2016.
- An increase in the target bonus for 2017 from 30% to 100% of his annual base salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document is limited to the disclosure of the executive compensation event.
Investor Verification Points
- Verify the total annual compensation impact for the CEO, including the new base salary and the potential 100% target bonus.
- Confirm the source of funds for the $250,000 one-time cash bonus.
- Review the Company's cash position to assess the liquidity impact of the increased salary and bonus obligations.